Health CareHealth Care Providers
  • Price (JPY)4,711.00
  • Today's Change179.00 / 3.95%
  • Shares traded4.40m
  • 1 Year change-33.30%
  • Beta1.3956
Data delayed at least 20 minutes, as of Aug 12 2022 07:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

M3 Inc is a Japan-based company mainly engaged in the provision of services centering on the platform of healthcare. The Company has five business segments. Medical Platforms segment conducts marketing-related businesses in Japan utilizing the Internet and real operations centered on medical employee specialized site m3.com. Evidence Solution segment is involved in the contract research organization (CRO) business that supports clinical development work and research, and site management organization (SMO) business that manages the clinical trial operations. Career Solutions segment is engaged in human resource services for healthcare professionals. Site Solution segment provides operational support for medical institutions and home-visit nursing services. Overseas segment provides services of medical related marketing support, research and careers, utilizing the medical employee specialized sites in the United States, the United Kingdom, China, Korea, India, France, Germany and Spain.

  • Revenue in JPY (TTM)218.75bn
  • Net income in JPY60.20bn
  • Incorporated2000
  • Employees9.38k
  • Location
    M3 Inc10FAkasaka Inter City, 1-11-44, AkasakaMINATO-KU 107-0052JapanJPN
  • Phone+81 362298900
  • Fax+81 362298922
  • Websitehttps://corporate.m3.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
2413:TYO since
Happiness-i Co LtdDeal completed27 Jul 202227 Jul 2022Deal completed22.91%--
eDoctores Soluciones SLDeal completed08 Jun 202208 Jun 2022Deal completed24.56%--
Canon Medical Systems Corp-Medical Accounting & EHR BusinessAnnounced25 Apr 202225 Apr 2022Announced10.46%--
Logic IncAnnounced01 Mar 202201 Mar 2022Announced10.35%--
3H Clinical Trial IncAnnounced25 Jan 202225 Jan 2022Announced2.95%--
Data delayed at least 20 minutes, as of Aug 12 2022 07:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
BayCurrent Consulting Inc61.81bn16.57bn641.85bn2.64k38.3115.1436.8610.381,078.041,078.044,022.182,728.181.2392.369.2523,429,110.0032.9321.0140.9326.3753.6747.1526.8021.012.94501.090.112125.1534.4527.3855.2249.2816.1854.02
SCSK Corp419.36bn32.77bn729.14bn14.94k22.222.9513.891.75104.97104.971,343.21791.301.0741.496.3028,073,100.008.338.9710.8412.5125.9325.427.828.352.43--0.25240.004.364.690.10473.30-0.71849.24
Square Enix Holdings Co Ltd351.55bn56.71bn758.67bn5.64k13.022.5711.782.16473.07473.072,931.232,399.131.001.608.8762,364,200.0016.219.6820.2512.6054.2848.8416.149.772.70--0.0030.819.857.3089.3420.553.7020.87
OTSUKA CORPORATION830.61bn39.12bn779.28bn9.17k20.042.6416.590.9519206.32206.324,380.811,565.151.6316.665.7090,568,640.007.788.9013.0514.7021.3220.824.774.721.91--0.020650.451.865.771.578.4010.4615.90
Rakuten Group Inc1.73tn-200.10bn1.04tn28.26k--1.01120.650.6058-126.57-126.571,093.10650.810.1097--7.0561,122,080.00-1.29-0.0704-1.31-0.0774-18.6652.30-11.71-0.5019----0.7898--15.5416.55-17.19--49.500.00
NEC Corp3.02tn127.19bn1.34tn117.42k10.490.874.120.442466.82466.8211,091.765,626.250.83797.883.8925,735,600.004.023.446.726.0829.1728.684.803.661.12--0.237620.150.67042.49-5.5738.929.5410.76
M3 Inc218.75bn60.20bn3.10tn9.38k52.0711.6644.8114.1788.6388.63322.06395.910.695--5.0623,311,060.0019.9117.7424.0522.4558.6558.2728.6524.03--1,100.440.0020.4223.0321.6568.8031.8832.9726.19
Fujitsu Ltd3.60tn175.81bn3.76tn124.22k20.792.279.451.04890.78890.7818,257.748,166.631.167.886.0429,011,730.006.785.4611.4310.1030.8228.885.854.541.22--0.126821.32-0.0798-2.79-9.8716.23-6.3219.57
Hitachi, Ltd.10.47tn498.40bn6.53tn368.25k13.011.405.770.6237515.44515.4410,828.184,805.020.78993.814.2228,423,810.004.384.058.487.9024.8126.055.554.630.7385--0.379826.5217.592.3016.1619.72-9.1313.97
Data as of Aug 12 2022. Currency figures normalised to M3 Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

27.27%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 29 Jan 202155.94m8.24%
Nomura Asset Management Co., Ltd.as of 30 Jun 202237.65m5.55%
Nikko Asset Management Co., Ltd.as of 30 Nov 202118.12m2.67%
Daiwa Asset Management Co. Ltd.as of 30 Jun 202216.73m2.46%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 30 Nov 202113.79m2.03%
The Vanguard Group, Inc.as of 08 Jul 202211.37m1.67%
Capital Research & Management Co. (World Investors)as of 30 Jun 20229.35m1.38%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 07 Jul 20229.06m1.34%
BlackRock Fund Advisorsas of 07 Jul 20227.70m1.13%
Norges Bank Investment Managementas of 31 Dec 20215.43m0.80%
More ▼
Data from 31 Dec 2021 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.